New

Brain-Derived Neurotrophic Factor: An Effective Biomarker for ECT Response in MDD?

Researchers found no association between depression severity and brain-derived neurotrophic factor (BDNF) levels, and no correlation between BDNF levels and response to electroconvulsive therapy.

New

Doctoring Thoughtfully Through Trauma-Informed Care

It’s no surprise that recent events, including the confirmation hearings for Supreme Court Justice Brett Kavanaugh, have elicited a number of painful memories for people across the United States.

New

Youths Who Use Marijuana Are at Increased Risk for Acute Psychotic Symptoms

Investigators examined whether adolescents who use marijuana heavily develop acute psychotic symptoms at a much higher rate than youths who use marijuana minimally or not at all.

New

Food Insecurity Increases Risk for Binge Eating Disorder and Obesity

Investigators observed a link between food insecurity — difficulty affording enough food to support regular, balanced meals — and increased probability of binge-eating disorder and obesity, according to study results.

New

How Should Clinicians Discuss Prognosis With Patients?

Talking to sick patients about their future health prospects is a challenge.

New

Aripiprazole, Bupropion Augmentation More Cost-Effective Than Just Bupropion

Investigators evaluated the cost-effectiveness of augmentation with either aripiprazole or bupropion in patients with depression compared with switching to a new antidepressant.

New

Valbenazine May Improve Movement Disorders in Patients With Mood Disorders

An analysis of once-daily valbenazine trials revealed improvements in tardive dyskinesia in patients with mood disorders.

New

Risk for Depression and Suicidal Ideation Elevated Among Patients With Atopic Dermatitis

Patients with atopic dermatitis have a higher likelihood of clinical depression and suicidality.

New

Ketamine May Be Equally Effective in Anxious vs Nonanxious Depression

Researchers found that there is a potential for the use of intravenous ketamine for anxious treatment-resistant depression.

New

FDA: Important Updates to the Clozapine REMS Program

Products covered under the Clozapine REMS program include Clozaril (HLS Therapeutics), Fazaclo (Jazz), and Versacloz (TruPharma), in addition to all generic versions.

New

Smoking Associated With Worsened Symptoms, Quality of Life in Patients With Psychosis

A negative association between number of cigarettes per day and quality of life was observed in patients with psychosis.

New

Insomnia Increases Emotional Dysregulation, Impulsivity, and Suicidality in Bipolar Disorder

Sleep has important functions for the regulation of mood and emotion, and treatment of sleep disturbances in bipolar disorder may improve patient outcomes.

New

NDA Submitted for Novel Insomnia Treatment Lemborexant

The NDA includes data from two Phase 3 clinical trials (SUNRISE 1 and SUNRISE 2) which included approximately 2000 patients.

New

Childhood Physical Violence Associated With Decreased Total Cholesterol

Investigators examine the link between decreased total cholesterol and childhood physical violence.

New

How the Government Shutdown Affects FDA Activities

The consequence of the shutdown means the budget appropriated by Congress for the Agency is on hold, resulting in ~7000 of it’s 17,000 employees being furloughed.

New

The Robot Will See You Now: The Increasing Role of Robotics in Psychiatric Care

Dr Pransky shares some examples of robots that have shown impressive psychiatric applications, as well as her thoughts on giving robots the critical role of delivering healthcare to human beings.

New

Extended-Release Naltrexone Improves Psychiatric Disorders During Addiction Therapy

Changes in anxiety, depression, or insomnia symptoms were examined in patients with opioid use disorder taking extended-release naltrexone or buprenorphine-naloxone.